National Research Corporation (NRC Health) has announced its financial results for the second quarter of 2025, highlighting a 2% sequential growth in Total Recurring Contract Value (TRCV). This marks the third consecutive quarter of TRCV growth and represents the highest sequential growth rate since the first quarter of 2021. CEO Trent S. Green expressed optimism about the company's continued momentum and customer enthusiasm for NRC Health's product portfolio. During the second quarter, NRC repurchased 381,736 shares at a weighted average price of $14.96 per share. In 2025, the company has returned a total of $16.1 million to shareholders through dividends and stock repurchases. The company's adjusted EBITDA margin was reported at 30% for the quarter, maintaining stability over the past year due to cost control initiatives and increased revenue per FTE. However, net margin stood at 0% for the quarter due to non-recurring cash bonuses and equity grants related to executive compensation arrangements following the transition from founder-led leadership. NRC Health also declared a quarterly cash dividend of $0.12 per share, payable on October 10, 2025, to shareholders of record as of September 26, 2025.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.